Skip to main content
ABIVAX logo

ABIVAX — Investor Relations & Filings

Ticker · ABVX ISIN · FR0012333284 LEI · 969500D8TMNB184OJU95 PA Manufacturing
Open in API
Filings indexed 872 across all filing types
Latest filing 2023-09-29 Interim / Quarterly Rep…
Country FR France
Listing PA ABVX

About ABIVAX

https://www.abivax.com

Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.

Recent filings

Filing Released Lang Actions
ABIVAX: RAPPORT FINANCIER SEMESTRIEL 2023
Interim / Quarterly Report Classification · 1% confidence The document is titled 'RAPPORT FINANCIER SEMESTRIEL 2023' (Semi-Annual Financial Report 2023) for Abivax. It contains comprehensive sections including management reports, consolidated financial statements (balance sheet, income statement, cash flow), and notes to the financial statements for the first half of the year. It is a full interim report, not an announcement or a summary, and thus fits the definition of an Interim/Quarterly Report. H1 2023
2023-09-29 French
ABIVAX: HALF-YEAR FINANCIAL REPORT 2023
Interim / Quarterly Report Classification · 1% confidence The document is titled 'HALF-YEAR FINANCIAL REPORT 2023' and contains comprehensive financial statements (consolidated statements of financial position, income, cash flows, etc.) for the first half of the year, along with an activity report and auditor's review. It is a full interim report, not an announcement or a summary, and therefore fits the definition of an Interim/Quarterly Report (IR). H2 2023
2023-09-29 English
Abivax annonce la publication de son rapport financier semestriel 2023
Report Publication Announcement Classification · 1% confidence The document is titled "Abivax annonce la publication de son rapport financier semestriel 2023" (Abivax announces the publication of its 2023 half-year financial report). It is very short (2033 characters) and explicitly states that the report is available on the company website, rather than containing the full financial data itself. This fits the definition of a Report Publication Announcement (RPA), which announces the release of another document, adhering to the 'MENU VS MEAL' rule. The document is announcing the release of an 'Interim / Quarterly Report' (IR), but the announcement itself is an RPA.
2023-09-29 French
Abivax announces the release of its 2023 half-year financial report
Report Publication Announcement Classification · 1% confidence The document explicitly states: "Abivax announces the release of its 2023 half-year financial report." It also contains the keyword "Half Year Report" and is very short (3003 characters), indicating it is an announcement about the report's availability rather than the report itself. A comprehensive half-year report would typically be classified as an Interim/Quarterly Report (IR). However, because this document is merely announcing the release and directing the user to the website, it fits the definition of a Report Publication Announcement (RPA).
2023-09-29 English
Rapport financier semestriel 2023
Interim / Quarterly Report Classification · 1% confidence The document is titled 'RAPPORT FINANCIER SEMESTRIEL 2023' (Semi-Annual Financial Report 2023) for Abivax. It contains comprehensive sections including management reports, consolidated financial statements (balance sheet, income statement, cash flow), and notes to the financial statements for the first half of the year. It is a full interim report, not an announcement or a summary, and thus fits the definition of an Interim/Quarterly Report. H1 2023
2023-09-29 French
Rapport CAC sur l'information fincière semestrielle
Interim / Quarterly Report Classification · 1% confidence The document is a 'Rapport Financier Semestriel 2023' (Interim Financial Report) for ABIVAX, covering the period from January 1, 2023, to June 30, 2023. It includes the auditor's report on the interim financial information, consolidated financial statements (balance sheet, income statement, cash flow statement), and detailed notes to the financial statements. As it contains substantive financial data and analysis for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. H1 2023
2023-09-29 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.